Invention Grant
- Patent Title: NLRX1 ligands
-
Application No.: US16460795Application Date: 2019-07-02
-
Publication No.: US10676436B2Publication Date: 2020-06-09
- Inventor: Josep Bassaganya-Riera , Andrew Leber , Raquel Hontecillas
- Applicant: Landos Biopharma, Inc.
- Applicant Address: US VA Blacksburg
- Assignee: LANDOS BIOPHARMA, INC.
- Current Assignee: LANDOS BIOPHARMA, INC.
- Current Assignee Address: US VA Blacksburg
- Agency: DeWitt LLP
- Agent Daniel A. Blasiole
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D211/04 ; A61P29/00 ; A61P35/00 ; C07D239/34 ; A61P31/12 ; A61P31/04 ; A61P3/10 ; A61P1/04 ; C07D403/14
Abstract:
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat multiple conditions, including inflammatory, immune-mediated, and/or chronic inflammatory gastrointestinal diseases; systemic immune-mediated diseases; cancers; and infectious diseases.
Public/Granted literature
- US20200010417A1 NLRX1 LIGANDS Public/Granted day:2020-01-09
Information query
